oicr.on.ca
Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Seed
Fund:
Compass Rose
Development of BCL6 inhibitors for the treatment of hematological cancers

Related news

OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers

OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.
    Please note that only Ontario-based innovations related to oncology and cancer care are eligible for FACIT's investment and commercialization support.